Similar articles

• Safety of reduced-antigen-content tetanus-diphtheria-acellular pertussis vaccine in adolescents as a sixth consecutive dose of acellular pertussis-containing vaccine.

  Zepp F, Knuf M, Habermehl P, Mannhardt-Laakmann W, Howe B, Friedland LR. Zepp F, et al. J Pediatr. 2006 Nov;149(5):603-610. doi: 10.1016/j.jpeds.2006.06.016. J Pediatr. 2006. PMID: 17095328 Clinical Trial.
• Prevention of pertussis among adolescents: recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine.

  America Academy of Pediatrics Commitee on Infectious Diseases. America Academy of Pediatrics Commitee on Infectious Diseases. Pediatrics. 2006 Mar;117(3):965-78. doi: 10.1542/peds.2005-3038. Epub 2005 Dec 28. Pediatrics. 2006. PMID: 16382131
• Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults.

  Mertsola J, Van Der Meeren O, He Q, Linko-Parvinen A, Ramakrishnan G, Mannermaa L, Soila M, Pulkkinen M, Jacquet JM. Mertsola J, et al. Clin Infect Dis. 2010 Sep 15;51(6):656-62. doi: 10.1086/655825. Clin Infect Dis. 2010. PMID: 20704493
• Tetanus-diphtheria-acellular pertussis vaccination of adults in the USA.

  Gidengil CA, Sandora TJ, Lee GM. Gidengil CA, et al. Expert Rev Vaccines. 2008 Jul;7(5):621-34. doi: 10.1586/14760584.7.5.621. Expert Rev Vaccines. 2008. PMID: 18564017 Review.
• The diphtheria and pertussis components of diphtheria-tetanus toxoids-pertussis vaccine should be genetically inactivated mutant toxins.

  Robbins JB, Schneerson R, Trollfors B, Sato H, Sato Y, Rappuoli R, Keith JM. Robbins JB, et al. J Infect Dis. 2005 Jan 1;191(1):81-8. doi: 10.1086/426454. Epub 2004 Nov 30. J Infect Dis. 2005. PMID: 15593007 Review.